An overview of Catalent Inc.’s (CTLT) institutional holdings

The price of Catalent Inc. (NYSE:CTLT) shares last traded on Wall Street rose 0.46% to $39.74.

Based on available information, 18 analysts follow Catalent Inc. (NYSE:CTLT). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $58.00 and a low of $40.00, we find $48.00. Given the previous closing price of $39.56, this indicates a potential upside of 21.33 percent. CTLT stock price is now -6.73% away from the 50-day moving average and -19.17% away from the 200-day moving average. The market capitalization of the company currently stands at $7.16B.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"


Among analysts, 9 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $49.08 as their price target over the next twelve months.

With the price target enhanced from $45 to $53, Robert W. Baird Upgraded its rating from Neutral to Outperform for Catalent Inc. (NYSE: CTLT).

In other news, Ryan Michelle R, Director bought 1,000 shares of the company’s stock on Aug 31. The stock was bought for $49,980 at an average price of $49.98. Upon completion of the transaction, the Director now directly owns 1,979 shares in the company, valued at $78645.46. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 30, Executive Chair GREISCH JOHN J bought 21,000 shares of the business’s stock. A total of $1,055,040 was incurred on buying the stock at an average price of $50.24. This leaves the insider owning 34,000 shares of the company worth $1.35 million. Insiders disposed of 15,468 shares of company stock worth roughly $0.61 million over the past 1 year. A total of 3.07% of the company’s stock is owned by insiders.

A candlestick chart of Catalent Inc. (NYSE: CTLT) showed a price of $40.40 on Thursday morning. During the past 12 months, Catalent Inc. has had a low of $31.45 and a high of $74.49. As of last week, the company has a debt-to-equity ratio of 1.27, a current ratio of 1.71, and a quick ratio of 1.19. The fifty day moving average price for CTLT is $42.61 and a two-hundred day moving average price translates $49.17 for the stock.

The latest earnings results from Catalent Inc. (NYSE: CTLT) was released for Sep, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.1, beating analysts’ expectations of -$0.14 by 0.04. This compares to $0.94 EPS in the same period last year. The net profit margin was -22.36% and return on equity was -22.01% for CTLT. The company reported revenue of $1.07 billion for the quarter, compared to $1.29 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -17.02 percent. For the current quarter, analysts expect CTLT to generate $1.04B in revenue.

Catalent Inc.(CTLT) Company Profile

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Related Posts